RIWC24 Sponsors

We are delighted to be joined by the esteemed sponsors below for the Retina International World Congress this June:

Johnson & Johnson is our headline Diamond Sponsor for RIWC24:

Johnson & Johnson, Diamond Sponsor of RIWC24

At Johnson & Johnson, good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, the company has aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most diversified healthcare products company, they are committed to using their reach and size for good. They strive to improve access and affordability, create healthier communities and put a healthy mind, body and environment within reach of everyone, everywhere.

Patients inform and inspire their science-based innovations, which continue to change and save lives. Applying rigorous science and compassion, Johnson & Johnson confidently addresses some of the most complex diseases of our time and unlocks the potential medicines of tomorrow. Johnson & Johnson continuously works to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way.

 

Abbvie is a Gold Sponsor of RIWC24:

sponsor

Abbvie‘s ~50,000 employees are scientists, researchers, communicators, manufacturing specialists and regulatory experts located around the globe. We devise with new approaches to addressing today’s health issues—from life-threatening illness to chronic conditions. We target specific difficult-to-cure diseases where we can leverage our core R&D expertise to advance science. We’re constantly working to create solutions that go beyond treating the illness to have a positive impact on patients’ lives, on societies—and on science itself.

We remember that, as healthcare grows ever more complex, the onus is on us to ensure that our medicines are understood by those who use them. We add value and get the best outcomes through the education, services and support we provide beyond our medicines.

Patients: Making an impact on more lives: To understand the patient journey, we collaborate with peers, academics, clinical experts, frontline professionals, governments and advocacy groups. This fuels us to develop and deliver new sustainable healthcare solutions that truly make a difference to patient outcomes and experiences.

Science: Finding better solutions to the world’s toughest challenges: Research and innovation are the cornerstones of our business. We advance leading-edge science through a dynamic and collaborative approach. This enables us to find better solutions for treating the world’s most challenging diseases. We focus on discovering, developing and delivering drugs in therapeutic areas where we have proven expertise—and can make an impact. 

Astellas is a Gold Sponsor of RIWC24:

AStellas sponsor

 

Astellas is committed to creating innovative drugs with cutting-edge science that can address areas of high unmet medical needs. We aim to help patients who have no treatment options, or do not respond adequately to existing treatments.

We strive to improve and enhance quality throughout the product lifecycle, not only in drug discovery, development, production, and commercial but also in post-marketing surveillance, safety information collection, and our collaborative work with medical professionals. Astellas conducts business in more than 70 countries and regions around the world, and in addition to complying with each country and region’s laws, regulations, and guidelines, we have established a system where all employees engage in business activities with high ethical standards and a broad perspective.

By taking advantage of next-generation modalities represented by cell therapy and gene therapy for patients with back of the eye diseases at high risk of blindness, we will provide new treatment options to replace, preserve and restore the function of cells critical for vision.

ASP7317, human embryonic stem cell-derived retinal pigment epithelial cells, is our lead program for geographic atrophy secondary to age-related macular degeneration and Stargardt disease in phase 1b clinical trial.
ASP2020, a universal donor cell-derived program, has recently entered into the pipeline. We believe universal donor cell technology is a powerful tool to solve or reduce the problem of immune rejection and to realize the ideal cell transplantation. Our product, Prograf® has been a globally leading drug in the transplantation field, and we have a strong passion for delivering safer transplantation therapy to more patients.

Astellas has the following capabilities:

  • Creation and manufacturing of high-quality PSC-derived differentiated cells and their development
  • Clinically applicable Universal Donor Cell technology for rejection-free cell transplantation
  • Safe gene-editing technology for the creation of the next generation cell therapy
  • Design, manufacturing and development of AAV-based gene therapy
  • Preclinical evaluation of cell and gene therapy candidates in the area of ophthalmology

Roche is a Silver+ Sponsor of RIWC24:

Silver Sponsor Roche

Roche 

Doing now what patients need next.

We’re revolutionising personalised healthcare

We bring the right treatments to the right patients at the right time. With our combined strengths in pharmaceuticals and diagnostics, we are better equipped to drive personalised healthcare forward.

We are focused on pioneering therapies to prevent vision loss, working to discover and develop innovative solutions, aiming to redefine standards of care for people living with vision impairment.

Challenge – A global issue: Worldwide, more than 1 billion people live with vision impairment that could have been prevented or has yet to be addressed.1 Millions of people live with eye conditions that increase their risk of sight loss.2 Visual impairment can have a devastating impact on those people affected, including patients and their caregivers.

Change in sight: With new approaches to the diagnosis and treatment of ophthalmic conditions being explored as we speak, this is a global health challenge that we at Roche are committed to and excited to tackle, alongside the low vision community.

Focus – A top priority: Our team is built around the experience of ophthalmologists, ophthalmic surgeons and retinal specialists, who bring on-the-ground insights to their work at Roche every day. We are innovating to improve diagnosis and transform patient experience and outcomes – by understanding the biology of ophthalmic conditions and what this means in practice to people living with vision loss.

Personalised approach: We partner with researchers, clinicians and patient groups from the low vision community to ensure we understand the needs of people experiencing vision loss – so we can try to meet these needs through our approach to innovation, our clinical trial programme and our medicines and technologies in development.

This means examining new data and analytical sources such as real world data, exploring new technologies like artificial intelligence and machine learning. Importantly, we’re developing digital health solutions to help better detect and monitor disease progression and pioneering new therapeutic options like gene therapy, working to deliver a personalised approach to eye health.

 

Boehringer Ingelheim is a Silver Sponsor of RIWC24:

Silver Sponsor Boehringer Ingelheim

At Boehringer Ingelheim we are driven by the desire to serve humankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. Our FOCUS articulates who we are and what we strive for, why we exist, how we work and what we want to achieve.

At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye. Visual impairment and blindness have a profound and devastating impact on the lives of the affected person, their families and society as a whole. Driven by our passion to improve care, we will transform the retinal health landscape by developing novel treatments and technologies, especially where nothing currently exists. Our ambition is clear – prevent vision loss in people at risk and preserve or restore vision in those with retinal diseases. Science and innovation are at the core of the comprehensive pipeline portfolio we have built in Retinal Health, with the first assets already in clinical development.

MeiraGTx is a Silver Sponsor of RIWC24:

meiragtx sponsor

MeiraGTx is a clinical-stage gene therapy company focused on developing potentially curative treatments for patients living with serious diseases. They currently have six programs in clinical development including four ocular indications, a salivary gland condition, and a Parkinson’s disease program. Their initial focus on diseases of the eye, salivary gland and central nervous system is based on the significant unmet medical need coupled with the high potential gene therapy has to provide meaningful clinical benefit in these areas. With headquarters in New York and London, their global footprint provides them the opportunity to partner with leading institutions around the world, allowing them to deepen their understanding of diseases and their progression.

 

Fountain Healthcare Partners is a Bronze+ Sponsor of RIWC24:

Fountain Healthcare Partners BRONZE PLUS sponsor

Fountain Healthcare Partners is a venture fund providing risk capital and expertise to ambitious entrepreneurs building outstanding life sciences companies with offices in Dublin, and New York. Founded in 2008, Fountain is Ireland’s largest dedicated life science venture capital fund with more than €294 million under management. Fountain invests in entrepreneurs and companies with disruptive technologies or products that have a clear pharmacoeconomic benefit and a defined pathway to commercialisation, value enhancement and exit.

Aramex is a Bronze Sponsor of RIWC24:

Aramex sponsor

With a firm commitment to excellence, reliability, and efficiency, Aramex offers a range of tailored B2B logistics services designed to meet the unique demands of your operations.

At Aramex Ireland, we understand the diverse and intricate needs of businesses in the logistics industry. 

Tailored Solutions:

Every business is unique, and so are its logistics requirements. We offer customized solutions that align seamlessly with your business objectives. Whether you need supply chain optimization, transportation management, or warehouse solutions, we’ve got you covered.

We specialise in providing end-to-end supply chain solutions that ensure the smooth flow of goods from point A to point B. Our dedicated team meticulously plans and executes logistics strategies tailored to your specific requirement.

We adhere to the highest industry standards and possess the necessary accreditations, expertise, and processes to guarantee compliance and quality assurance. Your products are in safe hands with us, meeting and exceeding the stringent quality benchmarks.

Apellis is a Bronze Sponsor of RIWC24:

Apellis Bronze Sponsor

At Apellis, we combine courageous science and compassion to develop life-changing medicines for some of the most challenging diseases patients face.  

We advance courageous science: Our goal is to transform treatment for a broad range of debilitating diseases by controlling a part of the immune system known as the complement cascade.  

We ushered in the first new class of complement medicine in 15 years, and now have two approved medicines targeting C3, the central protein in the cascade. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. 

With nearly a dozen clinical and pre-clinical programs underway, we believe we have only begun to unlock the potential of targeting C3 across many serious diseases. 

We deeply care about the needs of people living with debilitating retinal diseases. By listening and learning in our interactions with patients, caregivers, and patient advocacy groups, we are able to champion the patient voice throughout the drug development process.

Beacon Therapeutics is a Bronze Sponsor of RIWC24.

Beacon Therapeutics Bronze Sponsor

Transforming lives with pioneering ocular gene therapy

Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.

We have an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP) with two preclinical programs, one targeting dry age-related macular degeneration (dAMD) and another targeting cone-rod dystrophy (CRD).

Beacon Therapeutics also has access to a target generation technology platform that will identify, screen and search secreted proteins in the ophthalmology space.

We are supported by funds from Syncona and additional investors including Oxford Science Enterprises.

Occuco is a Bronze Sponsor of RIWC24.

Occuco Bronze Sponsor

Pioneers in software engineering in the eyecare space, we have a singular ambition: to harness cutting-edge technology to build the digital framework for the future of eyecare.

Our customer-driven philosophy and passion to bring innovative technology to the optical world are the foundation of our success. We strive to provide customers with flexible and simple solutions to meet the exact needs of optical businesses of any size.

Over 6,750 sites in 88 countries use Ocuco’s software and services. The company has over 350 staff globally with the largest hubs being in the USA, Canada, Ireland, the United Kingdom, Italy, Sweden, Norway, the Netherlands, Belgium and China.

Okuvision is a Bronze Sponsor of RIWC24.

Okuvision BRONZE sponsor

Okuvision is a Bronze sponsor of RIWC24.  Okuvision is a medical device company and a leading provider in the field of ocular electrical stimulation, based in Reutlingen, Germany. Okuvision manufactures and distributes the OkuStim® therapy system. The CE-marked OkuStim® offers patients with retinitis pigmentosa and similar hereditary retinal dystrophies a non-invasive treatment that delays disease progression. OkuStim® is available from an increasing distribution network, currently in ten European countries. Okuvision is in constant scientific and collaborative contact with leading eye hospitals

Progressive Vision is a Bronze Sponsor of RIWC24:

Progressive Vision BRONZE sponsor

Progressive Vision, our Bronze Sponsor, is a multidisciplinary eye clinic based in Dublin. They offer a unique patient-focused eye care experience with an emphasis on kindness and excellence delivered by their highly skilled and experienced team in a modern, comfortable setting. Mr Mark Cahill, Dr Mohamed El Morsy and Dr Fiona Darcy are the consultant ophthalmologists based at the clinic, specialising in general ophthalmology, cataract, age–related macular degeneration, glaucoma, cornea, diabetic eye disease, medical retina and vitreo-retinal surgery.

SparingVision is a Bronze Sponsor of RIWC24:

SparingVision bronze sponsor

TRANSLATING PIONEERING SCIENCE INTO VISION-SAVING TREATMENTS:  Moving beyond single gene correction therapies to deliver new treatments.

We are a clinical-stage genomic medicines company leading a step shift in how ocular diseases are treated. We are going beyond single gene correction therapies to deliver new treatments to patients affected by Inherited Retinal Diseases (IRDs), regardless of genetic cause.

Our goal is to harness the potential of gene therapy and genome editing to bring cutting-edge innovation into ocular disease drug discovery and development.

VivaQuity is a Bronze Sponsor of RIWC24:

VivaQuity bronze sponsor

VivaQuity Ltd. is a vision science company dedicated to the diagnostics, prevention, and counteraction of visual disturbances and chronic eye conditions.

The company is based in Waterford, Ireland, one of the world-leading centres of research for vision and nutrition.

The company provides Irish and international eye care professionals and patients with state-of-the-art tools for the prevention of chronic eye diseases. For this purpose, the company is always active in research and development.

VivaQuity currently offers a vision test for an accurate measurement across the spectrum of vision testing to maximise the potential of computer processing and tablet technology, eye health supplements, and educational risk assessment programs.

Fáilte Ireland is our official conference partner.

Failte Ireland Official Conference Partner

Fáilte Ireland works in partnership with Government, State agencies, Local Authorities, representative groups and industry, to develop tourism across Ireland by creating destination development plans and networks, investing in infrastructure, activities, visitor attractions and festivals. Fáilte Ireland also provides consumer and buyer insights, mentoring, business supports and training programmes and buyer platforms to help tourism businesses innovate and grow. The support of Fáilte Ireland adds immense value to our event, and we look forward to a collaborative and impactful RIWC24!

Learn more about the programme and agenda here.

With sincere thanks also for the support of Brtivic and Xavier Society for the Blind:

Xavier Society for the Blind and Britvic Bronze Sponsors

Xavier Society provides religious, spiritual, and inspirational reading materials in braille and audio to blind and visually impaired individuals worldwide. We are able to provide these materials free of charge thanks to the generous support of our donors. We support this community of faithful in understanding, developing and practicing their Faith. Our service began in 1900 and we hope to serve many more people in new and innovative ways for many years to come.

___ 

At Britvic, we strive to be the most dynamic soft drinks company, creating a better tomorrow. We offer consumers a range of family favourite and global premium brands. We exist to help people enjoy life’s everyday moments.